Stock HTBX SCORPIUS HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Scorpius Holdings, Inc.

Equities

HTBX

US42237K4094

Delayed OTC Markets
Other stock markets
 17:52:01 02/07/2024 BST 		5-day change 1st Jan Change
0.0255 USD -15.56% Intraday chart for Scorpius Holdings, Inc. -10.84% -94.21%
06-24 Scorpius Holdings, Inc.(OTCPK:SCPX) dropped from S&P TMI Index CI
06-14 Scorpius Holdings Faces Delisting by NYSE American; Trading Suspended MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Scorpius Holdings, Inc. and Beyond Imagination Announce Trailblazing Partnership to Utilize Autonomous AI-Powered Humanoid Robots for American Biomanufacturing
Scorpius Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Scorpius Holdings, Inc. Announces Major Expansion in San Antonio with New Storage and Testing Facility
Top Midday Decliners
Scorpius Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Scorpius Holdings, Inc. Wins Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University
Scorpius Holdings Prices Stock Offering at $0.15 a Share
Scorpius Holdings, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023
Nighthawk Biosciences, Inc. Announces the Promotion of Joe Payne to President and Chief Operating Officer of Its Scorpius Biomanufacturing Subsidiary
NightHawk?s Scorpius BioManufacturing Subsidiary Receives Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program
NightHawk Biosciences Postpones Planned Name Change
Nighthawk?S Scorpius Biomanufacturing Subsidiary Commences Work on Preclinical Program for New Client
NightHawk Biosciences, Inc. Announces Executive Appointments
NightHawk Biosciences, Inc. has Changed its Ticker to SCPX from NHWK
Scorpius BioManufacturing Commences Work on Multi-Million-Dollar Development and Manufacturing Agreement for A Leading National University
Jeffrey Wolf completed the acquisition of Elusys Therapeutics, Inc. from NightHawk Biosciences, Inc..
NightHawk Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
NightHawk Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
NightHawk Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
NightHawk Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HTBX Stock
  4. News Scorpius Holdings, Inc.
  5. Other languages